Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Wired August 2003 Jennifer Kahn	The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine.
Wired Thomas Goetz	Why Early Detection Is the Best Way to Beat Cancer By getting regular blood tests, doctors may be able to diagnose cancer early, giving the patient a 90 percent chance of survival.
Chemistry World January 21, 2011 Jennifer Newton	Early lung cancer diagnosis Patients with lung cancer have elevated levels of a specific protein in their blood that could be used as a biomarker for the disease, say scientists from South Korea.
Bio-IT World February 18, 2004	Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies
Bio-IT World Dec2006 /Jan 2007 Robert M. Frederickson	Microarrays for Methylation Recent data suggest altered gene methylation patterns contribute to tumor development. Orion Genomics has developed two methods for enzymatic DNA methylation screening.
Bio-IT World August 13, 2002 Malorye Branca	The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed?
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
Bio-IT World February 11, 2005 Robert M. Frederickson	Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
Bio-IT World August 13, 2003 Malorye Branca	Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm.
Bio-IT World February 18, 2004	Proteomics Goes Cellular Tissue microarrays save big on sample material and reagents. But more importantly, this new high-throughput technology is helping save the lives of cancer patients
Bio-IT World October 2005 Mark D. Uehling	HistoRx Automates Pathology The company offers a platform called Aqua, which can perform automated, in situ analysis of protein expression levels on tissue microarrays in less than an hour. The company has promising projects in melanoma and breast cancer.
Nurse Practitioner October 2009 Wallace et al.	Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education.
American Family Physician September 15, 2003 Perkins et al.	Serum Tumor Markers Because family physicians are assuming a greater role in caring for patients with cancer, an understanding of tumor markers is becoming increasingly important.
Scientific American March 2009 Elaine Schattner	A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
Bio-IT World July 2005 Robert M. Frederickson	Amassing Mass Spectrometry Tools Mass spectrometry is a key tool in the effort to identify protein biomarkers of human disease. Manufacturers have met major challenges in adapting this technology to protein discovery, both qualitatively and quantitatively.
American Family Physician September 15, 2005 Mark H. Ebell	Point-of-Care Guides What is the risk of prostate cancer in a patient who is referred for biopsy?
Pharmaceutical Executive September 1, 2005 Mattingly & Saxberg	Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
AskMen.com Jacob Franek	Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease.
American Family Physician March 15, 2001	Cancer Screening Guidelines Faced with the broad, and sometimes conflicting, range of recommendations for cancer screening, family physicians must determine the most reasonable and up-to-date method of screening...
HHMI Bulletin Nov 2010	Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers.
American Family Physician August 15, 2000 Sharon Scott Morey	AUA Issues a Policy Report on PSA Monitoring The American Urological Association (AUA) has released a policy report on the use of prostate-specific antigen (PSA) in screening for and monitoring of prostate cancer.
American Journal of Nursing September 2009 Lockwood-Rayermann et al.	Original Research: Women's Awareness of Ovarian Cancer Risks and Symptoms Objective: To assess how well informed women ages 40 and older are of ovarian cancer symptoms and risk factors.
Bio-IT World May 9, 2003 Julia Boguslavsky	MS Goes Through the Roof Mass spectrometry goes through the roof when the Mayo Clinic installs its new machine.
American Family Physician August 1, 2000 Lecia M. Apantaku	Breast Cancer Diagnosis and Screening Statistics on breast cancer risk, symptoms and recommended tests.
Managed Care February 2008 Thomas Morrow	As the Use of Biomarkers Grows, Managed Care Companies Will Face Tough Decisions About Setting Limits Health care faces difficult challenges as it increasingly incorporates a personalized approach that uses various biomarkers to influence medical decision-making.
Bio-IT World June 2006 Kevin Davies	The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine.
AskMen.com Jacob Franek	New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily.
American Family Physician December 15, 2005 Mark H. Ebell	Predicting the Risk of Recurrence After Surgery for Prostate Cancer Several clinical decision rules have addressed this question. The most widely validated score the PSA, clinical stage, and Gleason grade to predict recurrence, which is defined as a postoperative serum PSA of 0.4 ng per mL or higher, clinical evidence of recurrence, or the need for subsequent treatment.
American Family Physician February 1, 2001 Thomas J. Gates	Screening for Cancer: Evaluating the Evidence This article reviews the kind of evidence required to justify screening tests for cancer, with the goal of guiding family physicians through current and future screening controversies...
Chemistry World December 16, 2013 Michael Parkin	1024 samples analysed on a single chip Researchers in Switzerland have developed a microfluidic platform able to measure four protein biomarkers in over 1000 blood samples on a single microfluidic chip.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
Managed Care June 2007 Thomas Morrow	Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer.
The Motley Fool June 9, 2010 Denise Gellene	Gen-Probe Prostate Cancer Test Looks Promising The new test could eliminate need for painful biopsies.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
Chemistry World October 20, 2009 James Urquhart	Gold nanoparticles give super sensitive cancer test The recurrence of prostate cancer could soon be spotted years earlier thanks to a new highly sensitive test developed by US and Austrian researchers.
CIO May 29, 2014 Stephanie Overby	CIOs Join Forces to Battle Cancer A coalition of healthcare IT chiefs are on a mission to put cancer out of business and share IT best practices, technology tips, and personal support.
Chemistry World September 5, 2014 Katie Lian Hui Lim	Urine test could catch lung cancer early Lung cancer could be identified earlier, thanks to a new test that uses surface enhanced Raman spectroscopy to detect a cancer biomarker in urine.
Chemistry World February 11, 2009 Lewis Brindley	Prostate Cancer Biomarker Could Speed Diagnosis US researchers have identified a compound in urine that could be used to detect prostate cancer - and also to distinguish between benign and invasive forms of the disease.
The Motley Fool November 30, 2010 Brian Orelli	Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers.
BusinessWeek March 8, 2004 Arlene Weintraub	And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why.
The Motley Fool September 14, 2011 Frank Vinluan	Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Chemistry World August 19, 2009 Hayley Birch	Gold nanoparticles detect cancer Chinese scientists have used gold nanoparticles as ultrasensitive fluorescent probes to detect cancer biomarkers in human blood.
Chemistry World April 21, 2011 David Barden	RNA analysis raises hopes of early cancer diagnosis An improved method for diagnosing colorectal cancer without using invasive techniques has been developed by scientists in China.
Pharmaceutical Executive March 1, 2013 Keeling & Paz	Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.